Biotech ETF
Global X S&P Biotech is rated a buy with a stop loss of $48.55

Global X S&P Biotech is rated a buy with a stop loss of $48.55
Our current ASX200 Trade Table open positions include….
Transurban is under Algo Engine buy conditions. In a lower interest rate environment, TCL should see increased buying interest. The buying support range is $12.50 – $13.00.
Update 11/10:
Santos is under Algo Engine buy conditions.
CSL is under Algo Engine buy conditions.
CSL is under Algo Engine buy conditions.
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
Okta, Inc. – Class A Common is rated a buy.
Okta reported its Q2 FY25 earnings, where it saw its revenues grow 16% YoY to $646M.
{NAS.MCRN} is rated a buy.
Micron’s Fiscal Q4 results. The company delivered a strong quarter, beating guidance across the board, with revenue growing 93%.
Or start a free thirty day trial for our full service, which includes our ASX Research.